Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates

Thursday, May 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the advancements in hepatitis B virus antisense oligonucleotides that incorporate novel chemistries. These new candidates have demonstrated significantly improved properties compared to existing clinical options. This development could lead to more effective treatments for chronic HBV infection.
Price reaction · baseline $4.87 (2025-05-08 close) · hit after-hours · 1 other ALGS headline(s) in the window, move may be shared
day 0 close
-8%
day 1 · peak
+16.6%
day 3
+14.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Next generation oligonucleotides show improved properties.
  • Novel chemistries enhance efficacy compared to current candidates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What improvements do the new HBV oligonucleotides offer?

The new HBV antisense oligonucleotides demonstrate significantly improved properties compared to current clinical candidates.

What is the focus of the article?

The article focuses on advancements in hepatitis B virus antisense oligonucleotides incorporating novel chemistries.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare hepatitis B antisense oligonucleotides chronic HBV novel chemistries
Last updated: May 8, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →